Display options
Cite
Chen VL, Wright AP, Halligan B, et al. Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Hepatol Commun. 2019;3(8):1073-1084doi: 10.1002/hep4.1391.
Chen, V. L., Wright, A. P., Halligan, B., Chen, Y., Du, X., Handelman, S. K., Long, M. T., Kiel, D. P., & Speliotes, E. K. (2019). Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Hepatology communications, 3(8), 1073-1084. https://doi.org/10.1002/hep4.1391
Chen, Vincent L, et al. "Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis." Hepatology communications vol. 3,8 (2019): 1073-1084. doi: https://doi.org/10.1002/hep4.1391
Chen VL, Wright AP, Halligan B, Chen Y, Du X, Handelman SK, Long MT, Kiel DP, Speliotes EK. Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Hepatol Commun. 2019 Jun 18;3(8):1073-1084. doi: 10.1002/hep4.1391. eCollection 2019 Aug. PMID: 31388628; PMCID: PMC6671828.
Copy Download .nbib Format: NLM
Share it on

Hepatol Commun. 2019 Jun 18;3(8):1073-1084. doi: 10.1002/hep4.1391. eCollection 2019 Aug.

Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis.

Hepatology communications

Vincent L Chen, Andrew P Wright, Brian Halligan, Yanhua Chen, Xiaomeng Du, Samuel K Handelman, Michelle T Long, Douglas P Kiel, Elizabeth K Speliotes

Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine University of Michigan Health System Ann Arbor MI.
  2. Department of Computational Medicine and Bioinformatics University of Michigan Medical School Ann Arbor MI.
  3. Division of Gastroenterology Loma Linda University Health Loma Linda CA.
  4. Section of Gastroenterology Boston Medical Center, Boston University School of Medicine Boston MA.
  5. Hebrew SeniorLife Institute for Aging Research, Department of Medicine Beth Israel Deaconess Medical Center Boston MA.
  6. Harvard Medical School Boston MA.

PMID: 31388628 PMCID: PMC6671828 DOI: 10.1002/hep4.1391

Abstract

Up to 25% of patients with nonalcoholic fatty liver disease (NAFLD) are not obese but may have a fat or muscle composition that predisposes them to NAFLD. Our aim was to determine whether body composition parameters associate with NAFLD and to identify genetic contributors to this association. This study included two cohorts. The first included 2,249 participants from the Framingham Heart Study who underwent a computed tomography scan to evaluate hepatic steatosis, dual-energy x-ray absorptiometry testing to assess body composition, and clinical examination. Body composition parameters were normalized to total body weight. A subset of participants underwent genotyping with an Affymetrix 550K single-nucleotide polymorphism array. The second cohort, Michigan Genomics Initiative, included 19,239 individuals with genotyping on the Illumina HumanCoreExome v.12.1 array and full electronic health record data. Using sex-stratified multivariable linear regression, greater central body fat associated with increased hepatic steatosis while greater lower extremity body fat associated with decreased hepatic steatosis. Greater appendicular lean mass was associated with decreased hepatic steatosis in men but not in women. A polygenic risk score for lipodystrophy (regional or global loss of adipose tissue) was associated with increased hepatic steatosis, increased liver fibrosis, and decreased lower extremity fat mass.

References

  1. Circulation. 2004 Jan 27;109(3):433-8 - PubMed
  2. Am J Epidemiol. 2007 Jun 1;165(11):1328-35 - PubMed
  3. J Gastroenterol Hepatol. 2008 Jun;23(6):888-93 - PubMed
  4. Liver Int. 2008 Dec;28(10):1381-8 - PubMed
  5. J Gastroenterol Hepatol. 2008 Jun;23(6):894-9 - PubMed
  6. Hepatology. 2008 Aug;48(2):449-57 - PubMed
  7. Nat Genet. 2009 Nov;41(11):1199-206 - PubMed
  8. Gastroenterology. 2010 Apr;138(4):1346-56, 1356.e1-3 - PubMed
  9. Hepatology. 2010 Jun;51(6):1979-87 - PubMed
  10. Hepatology. 2010 Sep;52(3):904-12 - PubMed
  11. Gastroenterology. 2011 Jan;140(1):124-31 - PubMed
  12. PLoS Genet. 2011 Mar;7(3):e1001324 - PubMed
  13. Aliment Pharmacol Ther. 2012 Jan;35(2):238-47 - PubMed
  14. J Gastroenterol. 2012 May;47(5):586-95 - PubMed
  15. Obes Rev. 2012 Dec;13 Suppl 2:30-9 - PubMed
  16. Arterioscler Thromb Vasc Biol. 2013 Apr;33(4):863-70 - PubMed
  17. J Gastroenterol Hepatol. 2013 Sep;28(9):1507-14 - PubMed
  18. Am J Epidemiol. 2013 Jul 1;178(1):38-45 - PubMed
  19. Hepatology. 2014 May;59(5):1772-8 - PubMed
  20. Am J Cardiol. 2014 Jan 1;113(1):156-61 - PubMed
  21. Nat Rev Gastroenterol Hepatol. 2015 Feb;12(2):65-6 - PubMed
  22. Medicine (Baltimore). 2015 Mar;94(9):e573 - PubMed
  23. J Hepatol. 2015 Aug;63(2):470-6 - PubMed
  24. J Diabetes Investig. 2015 Mar;6(2):158-63 - PubMed
  25. Gastroenterology. 2015 Sep;149(3):635-48.e14 - PubMed
  26. Clin Genet. 2016 Apr;89(4):434-441 - PubMed
  27. Liver Int. 2015 Dec;35(12):2537-46 - PubMed
  28. J Gerontol A Biol Sci Med Sci. 2016 Mar;71(3):356-61 - PubMed
  29. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1463-1472.e6 - PubMed
  30. Nature. 2016 Aug 4;536(7614):41-47 - PubMed
  31. J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):789-795 - PubMed
  32. Nat Genet. 2016 Oct;48(10):1284-1287 - PubMed
  33. J Hepatol. 2017 Jan;66(1):123-131 - PubMed
  34. Sci Rep. 2016 Sep 12;6:33255 - PubMed
  35. J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511 - PubMed
  36. Nat Genet. 2017 Jan;49(1):17-26 - PubMed
  37. Aliment Pharmacol Ther. 2017 Feb;45(4):510-518 - PubMed
  38. Am J Clin Nutr. 2017 Mar;105(3):714-722 - PubMed
  39. Clin Endocrinol (Oxf). 2017 May;86(5):698-707 - PubMed
  40. Am J Hum Genet. 2017 Jul 6;101(1):37-49 - PubMed
  41. J Gerontol A Biol Sci Med Sci. 1998 May;53(3):M214-21 - PubMed

Publication Types

Grant support